{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T08:18:29Z","timestamp":1709626709140},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2013,11,13]]},"abstract":"\n Objective: <\/jats:title>\n Compare effectiveness of celecoxib versus diclofenac plus omeprazole in improving arthritis signs and symptoms in patients at high gastrointestinal (GI) risk who were enrolled in the CONDOR (Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis and Rheumatoid Arthritis) trial.<\/jats:p>\n <\/jats:sec>\n \n Methods: <\/jats:title>\n CONDOR was a 6-month, prospective, double-blind, triple-dummy, parallel-group, randomized, multicenter trial comparing celecoxib 200 mg twice daily versus diclofenac slow release (SR) 75 mg twice daily plus omeprazole 20 mg daily. Patients were Helicobacter pylori negative, had osteoarthritis (OA) or rheumatoid arthritis (RA), were aged \u226560 years, were with or without a history of gastroduodenal ulceration, or were \u226518 years with previous gastroduodenal ulceration. Patients\u2019 Global Assessment of Arthritis was determined at each study visit.<\/jats:p>\n <\/jats:sec>\n \n Results: <\/jats:title>\n A total of 4484 patients were randomized to treatment (2238 celecoxib, 2246 diclofenac SR) and included in the intention-to-treat analyses. Least squares mean (LSM) (standard error [SE]) for Patients\u2019 Global Assessment of Arthritis was 3.219 (0.017) and 3.221 (0.017) at baseline for celecoxib and diclofenac SR (p=0.90). Improvement in both groups was similar in months 2, 4, and 6; at month 1 the LSM (SE) was 2.647 (0.017) and 2.586 (0.017) for celecoxib and diclofenac (p=0.0025). LSM difference (SE) from baseline to final visit demonstrated an improvement of 0.75 (0.02) in celecoxib-treated patients and 0.77 (0.02) in diclofenac SR-treated patients (p=0.42).<\/jats:p>\n <\/jats:sec>\n \n Conclusions: <\/jats:title>\n Celecoxib and diclofenac plus omeprazole were shown to have similar efficacy in patients with OA and\/or RA at increased GI risk who were enrolled in the CONDOR trial.<\/jats:p>\n <\/jats:sec>\n \n Trial Registry: <\/jats:title>\n Trial was registered under ClinicalTrials.gov identifier NCT00141102.<\/jats:p>\n <\/jats:sec>","DOI":"10.2174\/1874312901307010096","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T07:41:22Z","timestamp":1385710882000},"page":"96-100","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial\u00a7"],"prefix":"10.2174","volume":"7","author":[{"given":"Herbert L.","family":"Kellner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret N.","family":"Essex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"Hochberg MC","year":"2012","unstructured":"Hochberg MC, Altman RD, April KT, et al. \n American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand hip and knee. \n Arthritis Care Res \n 2012; \n 64\n (4)\n : 465-74.","journal-title":"Arthritis Care Res"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"Smolen JS","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, et al. \n Treating rheumatoid arthritis to target: recommendations of an international task force. \n Ann Rheum Dis \n 2010; \n 69\n (4)\n : 631-7.","journal-title":"Ann Rheum Dis"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archinte.165.2.171","volume":"165","author":"Dai C","year":"2005","unstructured":"Dai C, Stafford RS, Alexander GC. \n National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. \n Arch Intern Med \n 2005; \n 165\n (2)\n : 171-7.","journal-title":"Arch Intern Med"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gtc.2009.03.007","volume":"38","author":"Lanas A","year":"2009","unstructured":"Lanas A, Sopena F. \n Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. \n Gastroenterol Clin North Am \n 2009; \n 38\n (2)\n : 333-52.","journal-title":"Gastroenterol Clin North Am"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJM199209103271101","volume":"327","author":"Allison MC","year":"1992","unstructured":"Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. \n Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. \n N Engl J Med \n 1992; \n 327\n (11)\n : 749-54.","journal-title":"N Engl J Med"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1542-3565(04)00603-2","volume":"3","author":"Graham DY","year":"2005","unstructured":"Graham DY, Opekun AR, Willingham FF, Qureshi WA. \n Visible small-intestinal mucosal injury in chronic NSAID users. \n Clin Gastroenterol Hepatol \n 2005; \n 3\n (1)\n : 55-9.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","volume":"376","author":"Chan FK","year":"2010","unstructured":"Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. \n Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. \n Lancet \n 2010; \n 376\n (9736)\n : 173-9.","journal-title":"Lancet"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","volume":"343","author":"Rodriguez GLA","year":"1994","unstructured":"Rodriguez GLA, Jick H. \n Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. \n Lancet \n 1994; \n 343\n (8900)\n : 769-2.","journal-title":"Lancet"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","volume":"343","author":"Langman MJ","year":"1994","unstructured":"Langman MJ, Weil J, Wainwright P, et al. \n Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. \n Lancet \n 1994; \n 343\n (8905)\n : 1075-8.","journal-title":"Lancet"},{"key":"refR10","year":"2012","unstructured":"U S Food and Drug Administration COX-2 selective (includes Bextra Celebrex and Vioxx) and non-selective non-steriodial anti-inflammatory drugs (NSAIDs) April 2005 US FDA website. \n Available at http:\/\/wwwfdagov\/Drugs\/DrugSafety\/PostmarketDr ugSafetyInformationforPatientsandProviders\/ucm103420htm Ac-cessed March 9 \n 2012.","journal-title":"Available at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDr ugSafetyInformationforPatientsandProviders\/ucm103420.htm Ac-cessed March 9"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","volume":"116","author":"Grosser T","year":"2006","unstructured":"Grosser T, Fries S, FitzGerald GA. \n Biological basis for the cardiovascular consequences of COX-2 inhibition therapeutic challenges and opportunities. \n J Clin Invest \n 2006; \n 116\n (1)\n : 4-15.","journal-title":"J Clin Invest"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/sarh.2002.37217","volume":"32","author":"Laine L","year":"2002","unstructured":"Laine L. \n The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. \n Semin Arthritis Rheum \n 2002; \n 32\n (3 )\n (Suppl 1 )\n : 25-32.","journal-title":"Semin Arthritis Rheum"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2007.03312.x","volume":"25","author":"Goldstein JL","year":"2007","unstructured":"Goldstein JL, Eisen GM, Lewis B, et al. \n Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole as assessed by video capsule endoscopy. \n Aliment Pharmacol Ther \n 2007; \n 25\n (10)\n : 1211-22.","journal-title":"Aliment Pharmacol Ther"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"Deeks JJ","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD. \n Efficacy tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis systematic review of randomised controlled trials. \n BMJ \n 2002; \n 325\n (7365)\n : 619.","journal-title":"BMJ"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","volume":"3","author":"Goldstein JL","year":"2005","unstructured":"Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. \n Video capsule endoscopy to prospectively assess small bowel injury with celecoxib. naproxen plus omepraole.and placebo. \n Clin Gastroenterol Hepatol \n 2005; \n 3\n (2)\n : 133-41.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","volume":"43","year":"2000","unstructured":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.Recommendations for the medical management of osteoarthritis of the hip and knee 2000 update American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. \n Arthritis Rheum \n 2000; \n 43\n (9)\n : 1905-5.","journal-title":"Arthritis Rheum"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2010.128660","volume":"70","author":"Burmester G","year":"2011","unstructured":"Burmester G, Lanas A, Biasucci L, et al. \n The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease opinions of a multidisciplinary European expert panel. \n Ann Rheum Dis \n 2011; \n 70\n (5)\n : 818-22.","journal-title":"Ann Rheum Dis"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1111\/j.1572-0241.2008.02200.x","volume":"103","author":"Chan FK","year":"2008","unstructured":"Chan FK, Abraham NS, Scheiman JM, Laine L. \n Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. \n Am J Gastroenterol \n 2008; \n 103\n (11)\n : 2908-18.","journal-title":"Am J Gastroenterol"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"Jordan KM","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M, et al. \n EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). \n Ann Rheum Dis \n 2003; \n 62\n (12)\n : 1145-55.","journal-title":"Ann Rheum Dis"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/ard.2004.028886","volume":"64","author":"Zhang W","year":"2005","unstructured":"Zhang W, Doherty M, Arden N, et al. \n EULAR evidence based recommendations for the management of hip osteoarthritis report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). \n Ann Rheum Dis \n 2005; \n 64\n (5)\n : 669-81.","journal-title":"Ann Rheum Dis"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"Emery P","year":"1999","unstructured":"Emery P, Zeidler H, Kvien TK, et al. \n Celecoxib versus diclofenac in long-term management of rheumatoid arthritis randomised double-blind comparison. \n Lancet \n 1999; \n 354\n (9196)\n : 2106-11.","journal-title":"Lancet"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/0091270008317590","volume":"48","author":"Schwartz JI","year":"2008","unstructured":"Schwartz JI, Dallob AL, Larson PJ, et al. \n Comparative inhibitory activity of etoricoxib celecoxib and diclofenac on COX-2 versus COX-1 in healthy subjects. \n J Clin Pharmacol \n 2008; \n 48\n (6)\n : 745-54.","journal-title":"J Clin Pharmacol"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"Silverstein FE","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, et al. \n Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study a randomized controlled trial.Celecoxib Long-term Arthritis Safety Study. \n JAMA \n 2000; \n 284\n (10)\n : 1247-55.","journal-title":"JAMA"},{"key":"refR24","first-page":"255","volume":"119","author":"Singh G","year":"2006","unstructured":"Singh G, Fort JG, Goldstein JL, et al. \n Celecoxib versus naproxen and diclofenac in osteoarthritis patients. \n SUCCESS-I Study Am J Med \n 2006; \n 119\n (3)\n : 255-66.","journal-title":"SUCCESS-I Study Am J Med"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","volume":"347","author":"Chan FK","year":"2002","unstructured":"Chan FK, Hung LC, Suen BY, et al. \n Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. \n N Engl J Med \n 2002; \n 347\n (26)\n : 2104-10.","journal-title":"N Engl J Med"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3899\/jrheum.090084","volume":"36","author":"Rohekar G","year":"2009","unstructured":"Rohekar G, Pope J. \n Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. \n J Rheumatol \n 2009; \n 36\n (10)\n : 2178-82.","journal-title":"J Rheumatol"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","volume":"74","author":"Bensen WG","year":"1999","unstructured":"Bensen WG, Fiechtner JJ, McMillen JI, et al. \n Treatment of osteoarthritis with celecoxib a cyclooxygenase-2 inhibitor a randomized controlled trial. \n Mayo Clin Proc \n 1999; \n 74\n (11)\n : 1095-5.","journal-title":"Mayo Clin Proc"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"Moore RA","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ. \n Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. \n Arthritis Res Ther \n 2005; \n 7\n (3)\n : R644-65.","journal-title":"Arthritis Res Ther"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"Simon LS","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, et al. \n Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. \n JAMA \n 1999; \n 282\n (20)\n : 1921-8.","journal-title":"JAMA"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/030097401750065265","volume":"30","author":"McKenna F","year":"2001","unstructured":"McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. \n Celecoxib versus diclofenac in the management of osteoarthritis of the knee. \n Scand J Rheumatol \n 2001; \n 30\n (1)\n : 11-8.","journal-title":"Scand J Rheumatol"},{"key":"refR31","unstructured":"Celebrex [package insert]. In: \n Inc New York NY: Pfizer 2013."}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V7\/TORJ-7-96\/TORJ-7-96.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V7\/TORJ-7-96\/TORJ-7-96.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V7\/TORJ-7-96\/TORJ-7-96.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T05:52:52Z","timestamp":1561096372000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/7\/PAGE\/96\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,11,13]]}},"alternative-id":["TORJ-7-96"],"URL":"https:\/\/doi.org\/10.2174\/1874312901307010096","relation":{},"ISSN":["1874-3129"],"issn-type":[{"value":"1874-3129","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2013-3-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-9-9","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-9-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}